2. Academic Validation
  3. Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2

Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2

  • J Med Chem. 2006 Jun 29;49(13):3766-9. doi: 10.1021/jm060347y.
Robert M Borzilleri 1,  Rajeev S Bhide,  Joel C Barrish,  Celia J D'Arienzo,  George M Derbin,  Joseph Fargnoli,  John T Hunt,  Robert Jeyaseelan Sr,  Amrita Kamath,  Daniel W Kukral,  Punit Marathe,  Steve Mortillo,  Ligang Qian,  John S Tokarski,  Barri S Wautlet,  Xiaoping Zheng,  Louis J Lombardo
Affiliations

Affiliation

  • 1 Bristol-Myers Squibb Pharmaceutical Research Institute, P.O. Box 4000, Princeton, New Jersey 08543-4000, USA. [email protected]
PMID: 16789733 DOI: 10.1021/jm060347y
Abstract

Substituted 3-((2-(pyridin-2-ylamino)thiazol-5-ylmethyl)amino)benzamides were identified as potent and selective inhibitors of vascular endothelial growth factor receptor-2 (VEGFR-2) kinase activity. The Enzyme kinetics associated with the VEGFR-2 inhibition of 14 (Ki=49+/-9 nM) confirmed that the aminothiazole-based analogues are competitive with ATP. Analogue 14 demonstrated excellent kinase selectivity, favorable pharmacokinetic properties in multiple species, and robust in vivo efficacy in human lung and colon carcinoma xenograft models.

Figures
Products